LVSI, lymphovascular space invasion; CCRT, concurrent chemoradiotherapy. Data are mean6SD or n (% per column) unless otherwise specified. Binary logistic regression test was used for P-value. A standardized difference of 0.10 or less indicates a good balance between the two groups. * Histologically assessed. † Both systemic chemotherapy and radiotherapy. Total number may not be 3,296 owing to missing data.

MPA yields a high response rate in APA, and if only younger patients are considered, a favorable pregnancy rate can be obtained. However, because recurrence rate is high, long-term follow-up under supervision of a trained gynecologic oncologist is required. To confirm MPA's utility, multi-center collaboration would be warranted.

for the Japanese Gynecologic Oncology Group IMPORTANCE The efficacy of taxane plus platinum regimens has been demonstrated for advanced or recurrent endometrial cancer; however, it has not been assessed in postoperative adjuvant chemotherapy for endometrial cancer.OBJECTIVE To evaluate the clinical benefit of taxane plus platinum compared with standard doxorubicin plus cisplatin as postoperative adjuvant chemotherapy in endometrial cancer. DESIGN, SETTING, AND PARTICIPANTSIn this multicenter, open-label, phase 3 randomized clinical trial, patients with endometrial cancer at high-risk stage I or II or stage III or IV that did not extend beyond the abdominal cavity and had 2 cm or greater residual tumor were included from 118 institutions in

The study data demonstrated that an OSNA assay using CK19 mRNA was applicable for detecting LN metastases in EC. Combined analysis using an OSNA assay and SLNs may improve individualized treatments according to LN metastatic status.